Stock Ratings / Health Care / INDP / options

DMAC (34) ARVN (37) OCS (58) AQST (27) ⌘ Pro Terminal →

Indaptus Therapeutics Inc. (INDP) Options Positioning, Max Pain & Unusual Sweeps

$3.34 +0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.34

Indaptus Therapeutics Inc. (INDP) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $513.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.34 (-0.14%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INDP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY INDP SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.51+4.8% Next Q

Q2 (-2Q)

Grade E$2.63+20.2% Next Q

Q3 (-1Q)

Grade E$3.16+5.7% Next Q

Current

Grade D-$3.34-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INDP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INDP currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.55) and Max Pain ($3.51) forces dealer call-delta covering toward $6.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INDP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INDP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (INDP)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for INDP.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INDP)

✓Walkthrough of INDP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INDP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.29%📐 HORIZONTAL RANGE

2026-10-30O $3.34H $3.40L $3.00C $3.34VOL 241.8K

RES: $3.93SUP: $0.92SMA50: $2.55SMA200: $2.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INDP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INDP Butterfly Map → + Track INDP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INDP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INDP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INDP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INDP)

Health Care Rank #780 of 1016 ⚔️ DMAC vs INDP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INDP vs. DMAC, ARVN, OCS, AQST)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Indaptus Therapeutics Inc. (INDP) ranks #780 by composite RQD confidence (36/100, grade D-) and #446 by equity capitalization ($513.0M). Within this direct 5-issuer industry benchmark cohort, INDP leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with INDP at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INDP ACTIVE Indaptus Therapeutics Inc.	D-	36/100	—	—	-35.0%	+0.30%	$513.0M	Benchmark Subject
DMAC DiaMedica Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.05%	$513.4M	/dmac-vs-indp →
ARVN Arvinas Inc.	D-	37/100	—	—	-32.1%	+3.95%	$516.6M	/arvn-vs-indp →
OCS Oculis Holding AG	D+	58/100	—	—	—	+3.26%	$507.5M	/ocs-vs-indp →
AQST Aquestive Therapeutics Inc.	E	27/100	—	58.3%	-35.0%	-4.49%	$507.1M	/aqst-vs-indp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001857044

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Indaptus Therapeutics Inc. (INDP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$20.8M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (-20.3% YoY). On the balance sheet, INDP closed FY2025 with $9.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$20.8M	-$14.8M	-$14.8M	$9.3M	—
FY2024 (FY)	2024-12-31	$0	-$15.0M	-$12.3M	-$12.3M	$7.3M	—
FY2023 (FY)	2023-12-31	$0	-$15.4M	-$13.4M	-$13.4M	—	—

3. INDP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Indaptus Therapeutics Inc. (NASDAQ: INDP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.34 (+0.30% 1D, market cap $513.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INDP ranks #780 in composite RQD confidence.

How does INDP compare to DMAC and ARVN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INDP carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DMAC (DiaMedica Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M) and ARVN (Arvinas Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M). Among the 5-stock peer group, INDP leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INDP?

Per INDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001857044), Indaptus Therapeutics Inc. generated $0 in revenue, -$20.8M in net income, and -$14.8M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INDP trading relative to its 50-day, 200-day, and 52-week technical levels?

INDP last traded at $3.34 (+0.30% on volume of 84,379 shares), positioning the stock +30.98% above its 50-day simple moving average ($2.55) and +45.85% above its 200-day simple moving average ($2.29). Across its 52-week range of $0.92 to $5.96, INDP sits at the 48.0% percentile with a 14-day RSI of 54.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.92 to $3.76).